Aridis pharmaceuticals announces exclusive license of suvratoxumab, a phase 3-ready monoclonal antibody, from astrazeneca

Los gatos, calif., july 19, 2021 /prnewswire/ -- aridis pharmaceuticals, inc. (nasdaq: ards) today announced that it has entered into an exclusive, worldwide licensing agreement with astrazeneca (lse/sto/nasdaq: azn) to in-license the late stage monoclonal antibody candidate, suvratoxumab.
ARDS Ratings Summary
ARDS Quant Ranking